These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39367456)

  • 1. Differential T-cell profiles determined by Hepatitis B surface antigen decrease among people with Human Immunodeficiency Virus /Hepatitis B Virus coinfection on treatment.
    Li X; Xu L; Lu L; Liu X; Yang Y; Wu Y; Zhu T; Li X; Li Y; Song X; Han Y; Lyu W; Cao W; Li T
    J Transl Med; 2024 Oct; 22(1):901. PubMed ID: 39367456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4
    Li X; Xu L; Lu L; Liu X; Yang Y; Wu Y; Han Y; Li X; Li Y; Song X; Cao W; Li T
    Front Cell Infect Microbiol; 2023; 13():1178788. PubMed ID: 37207191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss.
    Xiong S; Zhu D; Liang B; Li M; Pan W; He J; Wang H; Sutter K; Dittmer U; Lu M; Liu D; Yang D; Liu J; Zheng X
    EBioMedicine; 2021 Jul; 69():103464. PubMed ID: 34233260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers.
    Malagnino V; Cerva C; Teti E; Campogiani L; Compagno M; Foroghi Biland L; Saderi L; Armenia D; Salpini R; Svicher V; Sotgiu G; Iannetta M; Andreoni M; Sarmati L
    Sci Rep; 2021 Feb; 11(1):3965. PubMed ID: 33597631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.
    Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond R; Bowden S; Lewin SR; Sasadeusz J; Littlejohn M; Locarnini SL; Ruxrungtham K; Dore GJ
    PLoS One; 2013; 8(4):e61297. PubMed ID: 23593455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy.
    Malagnino V; Cerva C; Maffongelli G; Teti E; Foroghi Biland L; Cesta N; De Masi M; Stingone C; Armenia D; Svicher V; Salpini R; Andreoni M; Sarmati L
    Sci Rep; 2019 Aug; 9(1):11942. PubMed ID: 31420570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
    Maylin S; Boyd A; Delaugerre C; Zoulim F; Lavocat F; Simon F; Girard PM; Lacombe K
    Clin Vaccine Immunol; 2012 Feb; 19(2):242-8. PubMed ID: 22190396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients.
    Mitsumoto F; Murata M; Ura K; Takayama K; Hiramine S; Shimizu M; Toyoda K; Ogawa E; Furusyo N; Hayashi J
    J Infect Chemother; 2015 Apr; 21(4):264-71. PubMed ID: 25596071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
    d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
    J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of HBV and HCV coinfection on CD4 cells among HIV-infected patients: a longitudinal retrospective study.
    Silva CMD; Peder LD; Silva ES; Previdelli I; Pereira OCN; Teixeira JJV; Bertolini DA
    J Infect Dev Ctries; 2018 Nov; 12(11):1009-1018. PubMed ID: 32012132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.
    Jaroszewicz J; Reiberger T; Meyer-Olson D; Mauss S; Vogel M; Ingiliz P; Payer BA; Stoll M; Manns MP; Schmidt RE; Flisiak R; Wedemeyer H; Peck-Radosavljevic M; Rockstroh J; Cornberg M
    PLoS One; 2012; 7(8):e43143. PubMed ID: 22905219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection.
    Chang JJ; Sirivichayakul S; Avihingsanon A; Thompson AJ; Revill P; Iser D; Slavin J; Buranapraditkun S; Marks P; Matthews G; Cooper DA; Kent SJ; Cameron PU; Sasadeusz J; Desmond P; Locarnini S; Dore GJ; Ruxrungtham K; Lewin SR
    J Virol; 2009 Aug; 83(15):7649-58. PubMed ID: 19458009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
    Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL
    J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-infected patients in an HBV endemic area in Brazil.
    da Silva CM; de Peder LD; Guelere AM; Horvath JD; Silva ES; Teixeira JJV; Bertolini DA
    PLoS One; 2018; 13(9):e0203272. PubMed ID: 30192795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
    Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable.
    Kefalakes H; Jochum C; Hilgard G; Kahraman A; Bohrer AM; El Hindy N; Heinemann FM; Verheyen J; Gerken G; Roggendorf M; Timm J
    J Hepatol; 2015 Jul; 63(1):13-9. PubMed ID: 25646888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with clearance of hepatitis B virus surface antigen in patients infected with human immunodeficiency virus.
    Tsutsumi T; Sato H; Kikuchi T; Ikeuchi K; Lim LA; Adachi E; Koga M; Okushin K; Kawahara T; Koibuchi T; Yotsuyanagi H
    Medicine (Baltimore); 2020 Jul; 99(29):e21271. PubMed ID: 32702915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBV coinfection with HCV alters circulating Tfh cell distribution and impairs HCV neutralizing antibody responses.
    Wen B; Zhang J; Liu W; Tang P; Xie T; Huang L; Hu Y; Jin K; Zhang P; Liu Z; Niu L; Qu X
    J Viral Hepat; 2019 Aug; 26(8):1002-1010. PubMed ID: 30972873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 21 augments the hepatitis B virus-specific CD8+ T-cell response in vitro in patients coinfected with HIV-1.
    Ren G; Esser S; Jochum C; Schlaak JF; Gerken G; Schadendorf D; Dittmer U; Wu G; Yuan Z; Timm J
    AIDS; 2012 Nov; 26(17):2145-53. PubMed ID: 22948268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.
    Crane M; Sirivichayakul S; Chang JJ; Avihingsanon A; Ubolyam S; Buranapraditkun S; Thantiworasit P; Wightman F; Locarnini S; Matthews G; Dore GJ; Ruxrungtham K; Lewin SR
    J Virol; 2010 Mar; 84(6):2657-65. PubMed ID: 20053751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.